Agilent Technologies, Inc.

Agilent Technologies, Inc. is a global leader in analytical and life sciences instrumentation headquartered in Santa Clara, California. Founded in 1999 as a spin-off of Hewlett-Packard, the company designs, manufactures, and services chromatography, mass spectrometry, spectroscopy, cell analysis, and molecular diagnostics systems. In fiscal year 2025 Agilent generated US$6.95 billion in revenue with 6.7% year-over-year growth, employed approximately 18,000 people, and served more than 285,000 laboratories worldwide.

Corporate Snapshot

Agilent traces its roots to Hewlett-Packard's test and measurement and chemical analysis businesses. In 1999 HP split into HP (computing) and Agilent (measurement, chemical analysis, and medical), and Agilent subsequently divested its semiconductor business as Avago (now Broadcom) in 2005 and its electronic measurement division as Keysight Technologies in 2014. Today the company operates three principal businesses: Diagnostics and Genomics Group, Life Sciences and Applied Markets Group, and Agilent CrossLab, which together cover the full analytical workflow from discovery research through applied analysis to clinical diagnostics.

The company's product portfolio is anchored by best-in-class liquid chromatography (LC), gas chromatography (GC), and mass spectrometry (MS) platforms — including the 6495 triple quadrupole LC/MS and 6545 Q-TOF systems — used extensively in pharmaceutical development, food safety, environmental testing, and clinical research. Agilent also supplies cell analysis solutions such as flow cytometry and real-time PCR, and materials science tools including FTIR, UV-Vis, and atomic spectroscopy systems. Its CrossLab services business provides instrument repair, calibration, and laboratory consulting, generating high-margin recurring revenue.

Key Strengths

Agilent's principal strength is its installed base and laboratory franchise. With analytical equipment running in over 285,000 research and industrial laboratories globally, the company enjoys a durable recurring revenue stream from consumables, columns, reagents, and service contracts that is more resilient than pure instrument sales. The 2026 acquisition of Biocare Medical for US$950 million added more than 300 specialized immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH) antibody assays and instruments, significantly strengthening Agilent's position in oncology and pathology diagnostics — one of the fastest-growing segments in clinical testing.

Financially, Agilent has demonstrated strong recovery momentum. FY2025 revenue grew 6.7% to US$6.95 billion, with fourth-quarter core growth accelerating to 7.2%, signaling a rebound from the 2023-2024 biopharma capex downturn. The company maintains a self-manufacturing model with production and R&D facilities across the United States, Europe, and Asia, providing supply-chain control and localization advantages. Its diagnostics portfolio, including the Agilent Dako pathology franchise and SureFISH probes, positions the company as a critical supplier to the global precision medicine ecosystem.

Challenges & Outlook

Agilent's main challenges are macro-cyclical exposure and intensifying competition. The biopharmaceutical capital equipment market remains sensitive to interest rates, tariff policy, and China trade tensions, which slowed orders in early 2025 and created volatility in reported revenue due to currency fluctuations. In China, Agilent's second-largest market, domestic instrument manufacturers are increasingly competitive in mid-range chromatography and spectroscopy, pressuring pricing and market share.

Looking forward, Agilent expects continued mid-single-digit to low-double-digit growth driven by the Biocare Medical integration, expansion in proteomics and spatial biology, and the secular growth of biopharma discovery and clinical diagnostics. Management has guided for improving margins as the instrument cycle recovers, and the company remains committed to returning capital through buybacks and dividends. With its deep laboratory installed base, expanding diagnostics franchise, and disciplined capital allocation, Agilent is well positioned to maintain its status among the world's leading analytical instrumentation companies through 2026 and beyond.

VerityRank Score of 89/100